Skip to main content
SpringerLink
Log in

Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Acute myeloid leukemia (AML) relapse is often associated with a poor outcome, especially after allogeneic stem cell transplantation (Allo-SCT). In patients relapsing early after SCT treatment, options are further limited by the fear for increased toxicity. We report our experience with ARA-C and gemtuzumab ozogamicin (GO) combination in relapsed post-SCT AML patients. Therapy consisted of ARA-C (1 gr/m2) for 4 days followed by one dose of GO 9 mg/m2 on day 5 and was supported by donor stem cells when possible. Responding patients not developing graft versus host disease (GVHD) were eligible for immunotherapy with donor lymphocyte infusion (DLI) or a second Allo-SCT. Sixteen patients, median age 53 years (range 31–63), are included in this analysis. Patients underwent SCT for high-risk AML (n = 11) or AML relapse (n = 5), and 81 % had an early post-SCT relapse. Responses were achieved in 60 % of evaluable patients (CR-5 CRp-4). Median probabilities of survival (OS) and event-free survival (EFS) in the entire cohort, responding and non-responding patients were 103 and 76 days, 183 and 97 days, and 79 and 16 days, respectively. At 1-year follow-up, 25 % of patients were alive; however, all had relapse. Treatment resulted in grade 3–4 neutropenia and thrombocytopenia in all patients, and 27 % each had grade 3–4 hyperbilirubinemia or elevation of liver enzymes. One patient died during treatment due to intracranial hemorrhage. Of the six patients proceeding to second SCT or receiving DLI, three patients developed mild veno-occlusive disease (VOD). Combination therapy with ARA-C and GO after SCT results in short-term disease control and limited toxicity and could be considered for patients who are candidates for further immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. James K, Mangan SML (2011) Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol 2(2):73–82. doi:10.1177/2040620711402533

    Article  Google Scholar 

  2. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJM (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10):3197–3204. doi:10.1182/blood.V97.10.3197

    Article  Google Scholar 

  3. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496

    CAS  PubMed  Google Scholar 

  4. Filanovsky K, Shvidel L, Shtalrid M (2010) Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia. J Clin Oncol 28(7):e115–e116. doi:10.1200/JCO.2009.26.7930, author reply e117-8

    Article  PubMed  Google Scholar 

  5. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50(6):497–500

    Article  CAS  PubMed  Google Scholar 

  6. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ (2003) Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87–90

    Article  CAS  PubMed  Google Scholar 

  7. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27(10):887–891

    Article  CAS  PubMed  Google Scholar 

  8. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893–897

    Article  CAS  PubMed  Google Scholar 

  9. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, Baccarani M (2004) First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 28(9):987–990

    Article  CAS  PubMed  Google Scholar 

  10. Specchia G, Pastore D, Carluccio P, Spinosa G, Giannoccaro M, Rizzi R, Mestice A, Liso V (2007) Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 86(6):425–428

    Article  CAS  PubMed  Google Scholar 

  11. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau J-L (2008) Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 26(32):5192–5197. doi:10.1200/jco.2007.15.9764

    Article  CAS  PubMed  Google Scholar 

  12. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: cancer and leukemia group B study 19902. Leuk Res 35(3):329–333

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P (2014) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89(4):399–403. doi:10.1002/ajh.23653

    Article  CAS  PubMed  Google Scholar 

  14. Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30(1):23–28

    Article  CAS  PubMed  Google Scholar 

  15. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A (2007) Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol 4(8):491–495

    Article  CAS  PubMed  Google Scholar 

  16. Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T, Nakayama K, Inokuchi K, Tajika K, Dan K (2007) Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Leukemia 22(6):1273–1274

    Article  PubMed  Google Scholar 

  17. Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H (2009) Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Int J Hematol 90(5):643–647. doi:10.1007/s12185-009-0440-0

    Article  PubMed  Google Scholar 

  18. Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y (2010) Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med 220(2):121–126. doi:10.1620/tjem.220.121

    Article  CAS  PubMed  Google Scholar 

  19. Tachibana T, Tanaka M, Takasaki H, Numata A, Fujisawa S, Maruta A, Harada H, Mori H, Ishigatsubo Y, Kanamori H (2011) Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation. Int J Hematol 94(6):580–582. doi:10.1007/s12185-011-0967-8

    Article  PubMed  Google Scholar 

  20. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K (2007) Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 40(11):1027–1032

    Article  CAS  PubMed  Google Scholar 

  21. Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH (2008) Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 42(12):783–789

    Article  CAS  PubMed  Google Scholar 

  22. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721–727

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The data was partially presented as an abstract at ASH 2012.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel Hashomer, Israel

    Maya Koren-Michowitz, Hannah Maayan, Arie Apel, Noga Shem-Tov, Ronit Yerushalmi, Yulia Volchek, Abraham Avigdor, Avichai Shimoni & Arnon Nagler

  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Maya Koren-Michowitz, Abraham Avigdor, Avichai Shimoni & Arnon Nagler

Authors
  1. Maya Koren-Michowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Maayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arie Apel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noga Shem-Tov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ronit Yerushalmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yulia Volchek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abraham Avigdor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Avichai Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maya Koren-Michowitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koren-Michowitz, M., Maayan, H., Apel, A. et al. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation. Ann Hematol 94, 375–378 (2015). https://doi.org/10.1007/s00277-014-2229-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2229-3

Keywords

Search

Navigation